ArticleCancer cell international2025
DPEP2 suppresses metastasis via NF-κB-mediated epithelial-mesenchymal transition and M2 polarization in p53-loss non-small cell lung cancer.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The TP53 gene (encoding the human p53 protein) is mutated in about 50% of non-small cell lung cancer (NSCLC). Loss of p53 is closely related to tumor metastasis and immune regulation, contributing to malignant progression and poor prognosis. However, therapeutic strategies for p53-loss NSCLC are still relatively limited. We found that DPEP2 is a diagnostic marker and predicts better outcome and prognosis in NSCLC with mutant TP53, but not with wild-type TP53. Loss of p53 induced DPEP2 downregulation at cellular and tissue levels. Functionally, DPEP2 inhibited the invasion and migration abilities, and decreased F-actin fibers. Mechanistically, DPEP2 impeded epithelial-mesenchymal transition (EMT) via the MAP3K7-mediated NF-κB signaling. Immunological analysis suggested that low level of DPEP2 and high level of M1 macrophages led to poor prognosis, whereas patients with high level of DPEP2 and low level of M2 had the best survival. Subsequently, a co-culture system was established to verify the effect of DPEP2 on M2 macrophages. The results showed that DPEP2 inhibited M2 macrophages polarization in a NF-κB-dependent manner. In addition, we found that DPEP2 antagonized the tumor-promoting effects of M2 macrophages by depleting LTD4. In vivo experiments indicated that high DPEP2 levels resulted in fewer lung metastases and less M2 macrophage infiltration. Overall, our studies suggest that DPEP2 might be a promising therapeutic target for highly metastatic p53-loss NSCLC by inhibiting tumor metastasis and M2 macrophage capacity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.